A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
Completed · Phase 2 · NCT05630196
Conditions: Chronic Low-back Pain
At a glance
- Research payments reported, 2025
- $15,029
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 138
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3857210 (drug), Placebo (drug)
- Dates
- Started 2022-12-08; completion 2023-06-15
- Results posted
- Yes
The main purpose of this study is to assess whether LY3857210 is safe and efficacious in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
From ClinicalTrials.gov, last updated 2024-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $15,029 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rocky Mountain Clinical Research LLC $15,029
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.